secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYPHERPUNK TECHNOLOGIES INC. (CYPH)
CIK:        0001509745
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001104659-24-060199
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Leap Therapeutics reports Q1 2024 net loss of $13.8M; completes $40M private placement
--------------------------------------------------------------------------------

- Net loss of $13.8M for Q1 2024 vs $41.9M Q1 2023; decrease due to $29.6M IPR&D expense from Flame merger in prior year.
- Completed $40M private placement with Gilead and other investors; net proceeds $37.2M extend cash runway into Q2 2026.
- Expanded Part B of DeFianCe CRC study from 130 to 180 patients; enrollment expected late Q3/Q4 2024, data mid-2025.
- Part C of DisTinGuish GEJ/gastric cancer study fully enrolled (170 patients); initial data expected H2 2024 or early 2025.
- Cash and equivalents $54.9M at March 31, 2024; exclusive of April 2024 private placement proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509745/000110465924060199/0001104659-24-060199-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509745/000110465924060199/tm2414104d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-060199

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer